Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07533019 · ClinicalTrials.gov registry record · Phase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07533019 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 60 participants.
The verdict
NCT07533019, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.
Interventions
- DRUG Placebo
- DRUG LY4005130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-14 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07533019
The ClinicalTrials.gov registry entry for NCT07533019 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07533019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07533019 about?
NCT07533019 is a clinical study titled "A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo". The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to in...
What is the current status of trial NCT07533019?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-04-14. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07533019?
The interventions under investigation include: Placebo (DRUG), LY4005130 (DRUG).
Who is sponsoring clinical trial NCT07533019?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.